43 results about "With glomerular filtration rate" patented technology

The invention discloses a phosphatidylcholine gold nano CT (Computed Tomography) probe as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: step S1, preparing a phosphatidylcholine ligand NH2-MPC; step S2, synthesis of a gold nanocluster GS-Au25 is carried out; and S3, the GS-Au25 is modified with a PC ligand, and the PC-Au25 is prepared. The ultra-small gold nano CT probe PC-Au25 with an Au25 gold nano cluster as a core and phosphatidylcholine PC as a surface ligand is obtained by optimizing and screening the core size and the surface ligand property of ultra-small gold nano particles. Wherein the 2-methacryloyloxyethyl phosphorylcholine is used as a PC ligand for the first time to modify the surfaces of the ultra-small gold nanoparticles, so that the surface modification of the ultra-small gold nanoparticles is realized, and the ultra-small gold nanoparticles can be efficiently and freely filtered through the kidney. The CT probe can be applied to the determination of the glomerular filtration rate through a CT imaging or blood test method.

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

In an illustrative embodiment, systems and methods for treating kidney disease in a human patient are disclosed. A method includes advancing a collapsible array of RF electrodes through a urinary tract of the patient in collapsed form and into a position in or near a renal pelvis. The effector is deployed to an expanded form to engage at least a portion of an interior wall of the renal pelvis. RF energy delivered through the array of electrodes target afferent nerves proximate the interior wall of the renal pelvis to inhibit or destroy their function. eGFR of the patient can be raised after treatment according to the method.

Verdazil derivative compounds and compositions thereof, useful as contrast agents for biomedical imaging, are provided. The compounds and compositions of this disclosure can be used, for example, for quantitative and / or qualitative assessment of glomerular filtration rate (GFR) in subjects, providing a reliable and rapid assessment of renal function.

The invention discloses a prediction model of a glomerular filtration rate after cardio-pulmonary resuscitation, a construction method and application thereof. The method comprises the following steps: collecting and preprocessing sample data; determining an independent variable, a dependent variable and an end variable; screening independent influence factors, and evaluating a relationship between the independent influence factors based on a variance expansion factor; constructing a column graph prediction model based on the independent influence factors; performing accuracy evaluation on the prediction model based on the accuracy and the mean absolute error; performing calibration degree analysis on the prediction model through a calibration curve, Bland-Altman consistency evaluation and pairing T test; evaluating the prediction efficiency of the prediction model through an ROC curve and an AUC; and verifying the universality and extrapolation of the prediction model. The early prediction model of the glomerular filtration rate after cardio-pulmonary resuscitation is constructed, so that the probability of chronic kidney diseases can be predicted within 24 hours, early discovery and early intervention are realized, and the disease progress is delayed.

A system and method for diagnosing a patient's renal function, the method comprising delivering a first tracer agent, transmucosally applying a first excitation light to the first tracer agent at the first monitoring site, transmucosally receiving a first fluorescent light emitted from the first tracer agent at the first monitoring site, transforming the received first fluorescent light to produce a first fluorescence signal, processing the first fluorescence signal to determine a first decay rate, and processing the first decay rate of the first fluorescent light to determine a glomerular filtration rate of the patient.

The present invention consists of a digital, always-online computer system designed to optimize perioperative safety through the automated integration of clinical and laboratory parameters. Unlike conventional medical calculators, this system implements a reactive logic engine that simultaneously calculates glomerular filtration rate (CKD-EPI 2021) and scores multiple risk scales (Goldman, LEE, ASA, CHA2DS2-VASc, HAS-BLED) without duplicate data entry. The system includes a drug reconciliation algorithm that cross-references the bleeding risk of the surgical procedure with the patient's renal function, generating accurate recommendations for discontinuing or continuing high-risk medications (anticoagulants, antiplatelet agents, SGLT2 inhibitors) based on current clinical evidence.

The invention provides an SPECT / CT-based renal function determination method and device and a processing system, designs a novel renal function determination architecture, and combines a CT structure image to more accurately distinguish kidney tissues and perirenal tissues and extract more real double-kidney signals compared with a traditional scheme that SPECT images are used for sketching double-kidney ROI (Region of Interest). The high time resolution and the high spatial resolution are both considered, so that the time radioactivity curve and the glomerular filtration rate of the separated kidney can be accurately measured, the high-quality measurement requirement for the separated kidney function in clinical work is met, and high-quality diagnosis and treatment service can be provided for a patient.

The invention discloses application of disulfiram in preparation of a medicine for treating UMOD gene mutation type autosomal dominant renal tubulointerstitial nephropathy, and belongs to the field of biomedicine. The application comprises the application of the disulfiram in preparation of the medicine for treating the hereditary tubulointerstitial nephropathy. According to the invention, a new pathogenic mutation UMOD c.106Cgt is identified; according to the invention, the pathogenicity of the gene is verified through a UMODH36Y mouse model constructed by CRISPR / Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats / CRISPR associated 9). DSF intervention is adopted, the serum creatinine and glomerular filtration rate (tGFR) of mice can be remarkably improved, and renal interstitial inflammation and fibrosis are relieved. The discovery prompts that the DSF realizes the therapeutic effect of renal function protection-inflammation inhibition-fibrosis relief in an ADTKD-UMOD animal model through targeted regulation of a pyroptosis pathway, a novel therapeutic strategy is provided for ADTKD-UMOD, and the clinical transformation period can be remarkably shortened due to the characteristic of new use of old medicines. The discovery lays an experimental foundation for developing a precise treatment scheme for the hereditary renal tubulointerstitial disease.

The application belongs to the technical field of disease prognosis, and particularly relates to a marker for predicting the prognosis risk of an acute coronary syndrome patient and a system for predicting the prognosis risk. The application provides a marker for predicting the prognosis risk of an acute coronary syndrome patient, which comprises a biomarker and a chronic kidney disease index; the biomarker comprises NT-proBNP and RBP4; and the chronic kidney disease index is an eGFR index. The application also provides a system for predicting the prognosis risk of an acute coronary syndrome patient, which comprises a protein detection module, a chronic kidney disease index detection module, a prognosis score determination module and a prognosis risk evaluation module. The system for predicting the prognosis risk of the application effectively solves the technical problems that the existing GRACE score prognosis prediction method has low prediction accuracy in the East Asian population and has limited prediction value for long-term cardiovascular adverse event risks of more than 1 year.

This invention relates to compositions and methods relating to a combination of naturally-occurring active ingredients useful for the regulation of kidney and excretory system function. The combination of active ingredients, comprising vitamin B6, vitamin E, iron, roundhead lespedeza, birch leaf, and red bilberry, improves the function of kidney structures. The present invention may be used to achieve lower blood nitrogen content, including help to eliminate creatinine, urea, uric acid, by improving glomerular filtration and thus delaying hemodialysis. The present invention may be used to achieve a pronounced anti-inflammatory effect on the kidneys and the urinary tract. The present invention may also be used on its own or as a part of conventional treatment for a long time or indefinitely.

The invention belongs to the technical field of biological medicines, and particularly relates to application of EPA (eicosapentaenoic acid) plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy, which is characterized by treating diabetic nephropathy mouse models induced by high fat diet and streptozotocin and having insulin resistance and hyperglycemia accompanied by kidney lipid accumulation and glomerular filtration rate reduction, and particularly relates to application of EPA plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy. The treatment effect of the EPA plasmalogen on the diabetic nephropathy is observed; results show that the EPA plasmalogen has obvious effects of improving kidney functions and kidney ectopic lipid deposition on diabetic nephropathy mice induced by high fat diet and streptozotocin, and also has the effects of reducing blood sugar, improving blood fat, reducing insulin resistance and the like. The EPA plasmalogen is used for intervening the diabetic nephropathy for the first time, and an important basis is provided for clinically treating the diabetic nephropathy by using the EPA plasmalogen.

The present invention relates to a method for measuring glomerular filtration rate (GFR) ex vivo in a subject that has been administered a contrast agent and that has been subjected to computed tomography (CT) or magnetic resonance imaging (MRI) including an excretion phase, a plain scan phase, an arterial phase, and a renal parenchyma phase or a portal vein phase, the method includes the step of calculating contrast agent clearance from CT or MRI data using manual, automated or semi-automated segmentation software, thereby obtaining a measured GFR.

The invention discloses a device and equipment for predicting the death risk of a sepsis shock patient after hematopoietic stem cell transplantation and a storage medium. The invention further discloses a CARPET integral model for predicting the death risk of the sepsis shock patient after hematopoietic stem cell transplantation and a method for predicting the death risk of the sepsis shock patient after hematopoietic stem cell transplantation based on the CARPET integral model. According to the method, the death risk of a sepsis shock patient within 28 after hematopoietic stem cell transplantation can be predicted by measuring the albumin content, bilirubin content, PaO2 / FiO2, lactic acid content and glomerular filtration rate of the sepsis shock patient after hematopoietic stem cell transplantation and combining sepsis shock time. Compared with an SOFA scoring model, a calibration curve between 28-day death rates predicted and observed by the CARPET integral model shows better consistency, and DCA analysis shows that the clinical benefits of patients are more.

The invention discloses a multi-database data management method and system for IgA nephropathy treatment, and relates to the technical field of data management. According to the method, multi-source clinical data is collected, a structured data set is formed based on data quality scoring and conflict resolution, the disease course stage of a patient is dynamically recognized based on a biomarker and a glomerular filtration rate, and differentiated collection, storage, synchronization and access strategies based on the disease course stage of the patient are specifically generated; multi-database collaborative management is executed, and the management effect is iteratively optimized through the data collection integrity rate, the data synchronization timeliness rate, the storage resource utilization rate and the response time; the problem that the IgA nephropathy multi-source database management and synergy efficiency is low is effectively solved, and the accuracy and efficiency of IgA nephropathy multi-source data management are remarkably improved.

The invention provides a glomerular filtration rate estimation method and device for a patient with asymmetric double renal functions. The method comprises the following steps: acquiring basic information, clinical data, laboratory detection data and iconography data of a patient, wherein the iconography data comprises kidney volume, blood flow volume, cortex and medullary thickness and kidney function expression of the right kidney and the left kidney; by analyzing iconography data, a functional difference measurement coefficient for quantifying the asymmetry of double kidney functions is calculated. Thirdly, extracting a global feature vector of the patient by using a deep learning model, and performing fusion processing on the iconography data, the clinical data and the laboratory detection data to generate a comprehensive feature vector; and on the basis, the functional weights of the right kidney and the left kidney are adjusted according to the functional difference measurement coefficient, finally, the adjusted functional weights and the global feature vectors are input into a deep regression model, and a corrected GFR estimated value is obtained through calculation. And more accurate renal function evaluation can be provided according to the condition that double renal functions are asymmetric.

Systems, devices, and methods involve approaches for determining a calibration value for an individual, estimating a creatinine level using a chemical sensor (e.g., based on an optical property of a chemical sensor), and estimating a glomerular filtration rate (GFR) based, at least in part, on the calibration value and the creatinine level.

The invention relates to the technical field of medical care informatics, and discloses an osteoporosis prevention strategy analysis method and system, and the method comprises the steps: a discrete event sequence extraction module extracts clinical events from an electronic medical record; the parameter adaptive mapping module constructs a time scale scaling factor by using the glomerular filtration rate, performs reverse correction on the attenuation parameter of the risk pulse function, and determines positive correlation mapping of the attenuation rate and the clearing efficiency; the time domain overlay analysis module calculates an instantaneous bone loss index and generates a bone mineral density evolution trajectory; according to the method, physiological metabolism indexes are converted into time control variables of a mathematical model, dynamic distortion caused by individual metabolism differences is avoided, and quantification and early warning of the risk long-tail superposition effect in the body of a patient with metabolic hypofunction are achieved.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a traditional Chinese medicine composition for treating chronic kidney disease and its application. Its main active ingredients, by weight, include: Astragalus membranaceus 20-35 parts, Cuscuta chinensis 10-25 parts, Codonopsis pilosula 10-25 parts, Atractylodes macrocephala 10-20 parts, Poria cocos 10-25 parts, Dioscorea opposita 10-25 parts, Salvia miltiorrhiza 10-25 parts, and Coix lacryma-jobi 10-30 parts. Real-world cohort studies have shown that this traditional Chinese medicine composition for treating chronic kidney disease can significantly improve the survival rate of patients with chronic kidney disease, delay the decline in glomerular filtration rate, effectively reduce the risk of kidney disease progression, and has good safety.

A method, system, and medium for dynamically controlling infusion drip rate based on patient physiological parameters include: acquiring real-time physiological parameter data, medical history data, and drug attribute data of the patient; real-time physiological parameter data including glomerular filtration rate and B-type natriuretic peptide concentration; obtaining a safe drip rate range based on one or more of the real-time physiological parameter data, medical history data, and drug attribute data according to a preset rule base; calculating a recommended drip rate based on a machine learning model and a standard drip rate; obtaining a preset drip rate threshold range, and generating and outputting a first drip rate control command based on the recommended drip rate, the safe drip rate range, and the preset drip rate threshold range; monitoring the actual drip rate in real time and calculating the error value between the actual drip rate and the recommended drip rate; and dynamically adjusting the first drip rate control command based on the error value using a closed-loop control algorithm to generate and output a second drip rate control command.

Methods, systems, and apparatus for determining glomerular filtration rate (GFR) by acquiring a measurement dataset. Furthermore, this disclosure includes: acquiring a measurement dataset comprising multiple measurement entries acquired before and after administration of an exogenous fluorescent agent; generating an intrinsic fluorescence (IF) signal, the IF signal representing the detected fluorescence intensity emitted from the exogenous fluorescent agent within a diffuse reflective medium; determining whether the IF signal includes a portion of early fluorescence data; after determining this portion of the early fluorescence data, identifying an operable IF signal range by filtering the IF signal associated with the early fluorescence data; determining a GFR value in the patient based on the rate of change of the operable IF signal; and providing the GFR value.

The present application provides compositions and systems for renal function assays. The present disclosure relates to systems and methods for determining glomerular filtration rate or assessing renal function in a patient in need thereof. The system includes a computing device, a power source, one or more sensors, and at least one tracer that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using a sensor, and the glomerular filtration rate of the patient is calculated using the rate of fluorescence reduction in the patient.

The invention discloses a pharmaceutical composition for treating chronic kidney disease stage 1-3 as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition consists of 40-60 parts of astragalus membranaceus, 40-60 parts of black soybeans, 8-12 parts of angelica sinensis, 24-36 parts of dogwood and 8-12 parts of rhodiola rosea. The preparation method comprises the following steps: pretreating the raw materials, soaking, boiling for several times and filtering to obtain a finished product. Based on the treatment principles of tonifying qi, activating blood, dredging collaterals and removing blood stasis in traditional Chinese medicine, the traditional Chinese medicine composition conforms to the pathogenesis of chronic kidney disease deficiency in root and excess in superficies, all the components synergistically play a role, the serum urea nitrogen, serum creatinine level and glomerular filtration rate of a patient can be improved and edema, weakness and other symptoms can be relieved by combining basic treatment, the total effective rate reaches 83.33%, and the traditional Chinese medicine composition is good in safety, easy and convenient to prepare and suitable for clinical application. The traditional Chinese medicine composition is suitable for long-term administration of patients with spleen and kidney qi deficiency and blood deficiency with stasis syndrome type chronic kidney diseases at 1-3 stages, and has good application value in treatment of related diseases.

The invention provides a method and a model for predicting the risk of early renal function decline after renal partial resection of a renal cell carcinoma patient. According to the method, clinical parameters of a patient are obtained through a preoperative nomogram or preoperative-intraoperative combined nomogram prediction model, risk integrals of all the parameters are distributed, a total integral is calculated, and the postoperative early renal function decline prediction probability is determined and visually output. The parameters of the preoperative nomogram prediction model comprise age, diabetes history, preoperative estimated glomerular filtration rate, kidney score and radiomics score; the joint model newly increases the intra-operative ischemia time. Model construction comprises the steps of CT image standardization, region segmentation, radiology feature extraction and preprocessing and the like, and can assist in clinical accurate assessment of risks and optimization of treatment decisions.

The disclosure is directed to methods and apparatus for the determination, diagnosis, progression and prognosis of kidney disease and mortality associated with kidney disease. The disclosure includes methods for determining renal function, in particular estimating glomerular filtration rate (GFR), in an animal. GFR can be useful in the diagnosis and treatment of kidney disease or dysfunction. In various aspects, the disclosure is directed to the use of free symmetrical dimethylarginine (SDMA) and creatinine in blood samples from animals, in particular cats and dogs, to determine glomerular filtration rate and kidney disease.

The application provides a kind of prediction method and model of early renal function decline risk of renal cell carcinoma patient after partial nephrectomy.Methods obtain patient clinical parameters by preoperative nomogram or preoperative-intraoperative joint nomogram prediction model, assign each parameter risk score and calculate total score, determine the prediction probability of early postoperative renal function decline and can be visualized output.Preoperative nomogram prediction model parameters include age, history of diabetes, preoperative estimated glomerular filtration rate, kidney score and radiomics score;Intraoperative ischemia time is added to the joint model.Model construction is standardized by CT image, region segmentation, radiology feature extraction and preprocessing, etc., which can assist clinical precise risk assessment and optimize treatment decision.

The present disclosure provides, inter alia, methods for treating lupus nephritis in an individual that has lupus. In some embodiments, in the individual has one or more of the following: a baseline urine protein-to-creatinine ratio (UPGR) of greater than or equal to about 2.0 g / g; a baseline estimated glomerular filtration rate (eGFR) that is less than or equal to 90 mL / min / 1,73m2; a baseline serum sample that is positive for anti-double-stranded DNA (anti-dsDNA) antibodies; a baseline serum sample that has a low C3 complement level: a baseline serum sample that has a low C4 complement level; no prior history or diagnosis of lupus and / or lupus nephritis; concomitant class V lupus nephritis; and / or is female.

The present application relates to the technical field of health care informatics, and discloses an osteoporosis prevention strategy analysis method and system, comprising: a discrete event sequence extraction module extracts clinical events from electronic medical records; a parameter self-adaptive mapping module constructs a time scale scaling factor using glomerular filtration rate to correct the decay parameter of the risk pulse function in reverse, and establish a positive correlation mapping between the decay rate and the clearance efficiency; a time domain superposition analysis module calculates the instantaneous bone loss index and generates the bone density evolution trajectory; and a strategy reverse optimization module simulates intervention superposition to screen the optimal strategy. The present application converts physiological metabolism indicators into time control variables of mathematical models, avoids kinetic distortion caused by individual metabolic differences, and realizes the quantification and early warning of the risk long tail superposition effect in patients with reduced metabolic function.

Verazyl derivative compounds and compositions thereof for use as contrast agents for biomedical imaging are provided. The compounds and compositions of the present disclosure are useful, for example, for quantitative and / or qualitative assessment of glomerular filtration rate (GFR) in a subject, providing reliable and rapid assessment of renal function.

The invention discloses a chronic kidney disease interstitial fibrosis and cellular crescent body prediction model and application thereof. The prediction model comprises a kidney interstitial fibrosis prediction model and a cellular crescent body prediction model. The renal interstitial fibrosis prediction model is Logit (P1) =-0.035 * estimated glomerular filtration rate (ml / min / 1.73 m < 2 >) + 0.030 * albumin (g / L)-0.039 * hematocrit (%) + 0.036 * RBC distribution width SD (fL)-0.212 * CD4 + / CD8 + T lymphocyte ratio + 0.313; wherein P1 is a severe renal interstitial fibrosis probability value; the cell crescent body prediction model is Logit (P2) =-0.032 * age (age)-0.766 * sex-1.047 * high density lipoprotein (mmol / L)-0.011 * estimated glomerular filtration rate (ml / min / 1.73 m < 2 >)-0.233 * ln (CD3 + CD4 + T lymphocyte count) (piece / l) + 0.670 * ln (urine erythrocyte count) ( / l) + 1.530; wherein P2 is a cellular crescent body formation probability value. The prediction model provided by the invention greatly improves the prediction ability of renal interstitial fibrosis and cellular crescent body, and has significant clinical application value.